Maxim Group
http://www.maximgrp.com/Maxim Group is a financial services firm that provides investment banking, asset management, research, and sales & trading to a diverse range of corporate clients, institutional investors and high net worth individuals.
The firm’s research division uses fundamental research and a “bottom up” approach to making investment recommendations. Maxim’s research analysts focus on under-covered, small- to mid-cap names in a variety of sectors including healthcare, technology, retail and others.
View Older Stories View More Recent Stories
-
Maxim Group Starts Co-Diagnostics (CODX) at Buy
-
Maxim Group Starts Cerecor (CERC) at Buy
-
Powerbridge Technologies Co., Ltd. Announces Closing of $8,750,000 Firm Commitment Initial Public Offering
-
Powerbridge Technologies Co., Ltd. Announces Closing of $8,750,000 Firm Commitment Initial Public Offering
-
Pluristem Therapeutics (PSTI) Prices 27.14 Share and Warrants Offering at $0.70/Sh
-
Pluristem Therapeutics Inc. Announces Pricing of Its Public Offering and Registered Direct Offering for Aggregate Proceeds of Approximately $20 Million
-
Maxim Group Starts Dynatronics (DYNT) at Buy
-
Inovio Pharmaceuticals (INO) Presents Positive dBiTE Data At AACR - Maxim
-
Maxim Group Starts Famous Dave's of America (DAVE) at Buy
-
Powerbridge Technologies Co., Ltd. (PBTS) Prices 1.7M Share IPO at $0.00167/Sh
-
Powerbridge Technologies Co., Ltd. Announces Pricing of Initial Public Offering
-
Powerbridge Technologies Co., Ltd. Announces Pricing of Initial Public Offering
-
Maxim Group Downgrades Genprex (GNPX) to Hold
-
Turtle Beach Corporation (HEAR) Investor Presentation Undercuts Guidance But Maxim Group Sees Substantial Long Term Value In Acquisition
-
Parallax Health Sciences Reports 2018 Operating and Financial Results Records Net Income of $16.3 Million
-
Maxim Group Reiterates Buy Rating on VolitionRX (VNRX) on Fosun Long March MOU
-
Maxim Group Downgrades Proteon Therapeutics (PRTO) to Hold
-
Maxim Group Reiterates Buy Rating, $20 PT on Viking Therapeutic (VKTX)
-
Moleculin Biotech (MBRX) Prices Underwritten Public Offering of Common Stock and Warrants
-
Moleculin Announces Pricing Of Underwritten Public Offering
-
Atossa Genetics (ATOS) PT Raised to $9 at Maxim Group
-
Pre-Open Stock Movers 03/26: (ALDX) (BBBY) (BIOC) Higher; (CCL) (MYOK) (RCL) Lower (more...)
-
Maxim Group Starts Biocept (BIOC) at Buy
-
Maxim Group Downgrades SELLAS Life Sciences Group (SLS) to Hold
-
Maxim Group Downgrades ContraVir Pharma (CTRV) to Hold
-
Moleculin Biotech (MBRX) Enrolled It First Two Patients In European Clinical Trial - Maxim
-
Maxim Group Starts INmune Bio Inc. (INMB) at Buy
-
Maxim Group Starts LiveXLive Media (LIVX) at Buy
-
AzurRx Biopharma (AZRX) Could Build Awareness For MS1819 At DDW - Maxim
-
Maxim Group LLC Announces Strategic Promotion In Healthcare Investment Banking
-
Maxim Group Downgrades Restoration Robotics (HAIR) to Hold
-
Biocept (BIOC) Prices 5.95M Share Registered Direct Offering for Gross Proceeds of $8.2M
-
Biocept Announces Pricing of $8.2 Million Registered Direct Offering
-
BioLife Solutions (BLFS) PT Raised to $24 at Maxim Group
-
Coffee Holding Co. (JVA) PT Lowered to $10 at Maxim Group
-
Viking Therapeutic (VKTX) PT Lowered to $20 at Maxim Group, Remains Bullish
-
Aegis Capital Corp. is pleased to announce Joseph T. Rallo and David W. Boral have joined the firm as Co-Heads of Investment Banking
-
Pareteum Corp (TEUM) PT Raised to $9 at Maxim Group
-
BioTime Announces Closing of Acquisition of Asterias Biotherapeutics Creating Leading Cell Therapy Company
-
American Resources Corporation Announces Full Exercise and Closing of Underwriters' Over-Allotment Option in Connection with its Underwritten Public Offering
-
EMCOR Group (EME) PT Raised to $73 at Maxim Group
-
Proteon Therapeutics (PRTO) Shares Look Attractive Ahead Of Phase 3 Data - Maxim
-
Horizon Technology Finance (HRZN) PT Raised to $13.50 at Maxim Group
-
Genco Shipping (GNK) PT Lowered to $20 at Maxim Group; Remains Top Pick
-
Hemispherx Biopharma Announces $5.3 Million in Expected Gross Proceeds from Recently Expired Rights Offering
-
Hemispherx Biopharma Announces $5.3 Million in Expected Gross Proceeds from Recently Expired Rights Offering
-
Xenetic Biosciences (XBIO) Prices $3.1M Registered Direct Offering
-
Xenetic Biosciences Announces Pricing of $3.1 Million Registered Direct Offering
-
Inovio Pharmaceuticals Completes Sale of Additional Convertible Senior Notes
-
Hemispherx Biopharma Announces Extension of Rights Offering Period to March 5, 2019

